

Effects of Calcium, Magnesium, and Potassium Concentrations on Ventricular Repolarization in Unselected Individuals

Raymond Noordam, PhD,^{a,*} William J. Young, MBBS,^{b,c} Reem Salman, BSc,^c Jørgen K. Kanthers, MD,^{d,e} Marten E. van den Berg, MD, PhD,^f Diana van Heemst, PhD,^a Henry J. Lin, MD,^{g,h,i} Sandhi Maria Barreto, MD, PhD,^j Mary L. Biggs, PhD, MPH,^k Ginevra Biino, PhD,^l Eulalia Catamo, PhD,^m Maria Pina Concas, MS,^m Jun Ding, PhD,ⁿ Daniel S. Evans, PhD, MPH,^o Luisa Foco, PhD,^p Niels Grarup, MD, PhD,^e Leo-Pekka Lyytikäinen, MD,^q Massimo Mangino, PhD,^{r,s} Hao Mei, PhD,^t Peter J. van der Most, PhD,^u Martina Müller-Nurasyid, PhD,^{v,w,x} Christopher P. Nelson, PhD,^{y,z} Yong Qian, MS,ⁿ Linda Repetto, MScR,^{aa} M. Abdullah Said, BSc,^{bb} Nabi Shah, PhD,^{cc,dd} Katharina Schramm, PhD,^{vw} Pedro G. Vidigal, MD, PhD,^{ee} Stefan Weiss, PhD,^{ff,gg} Jie Yao, MD, MS,^g Nuno R. Zilhao, PhD,^{hh} Jennifer A. Brody, BA,ⁱⁱ Peter S. Braund, PhD,^{y,z} Marco Brumat, MS,^{jj} Eric Campana, MS,^{jj} Paraskevi Christofidou, PhD,^{ff} Mark J. Caulfield, MD,^{c,kk} Alessandro De Grandi, PhD,^p Anna F. Dominiczak, MD,^{ll} Alex S.F. Doney, PhD,^{cc} Gudny Eiriksdottir, MSc,^{hh} Christina Ellervik, MD, PhD,^{mm,nn,oo,pp} Luana Giatti, MD, PhD,^j Martin Gögele, PhD,^p Claus Graff, PhD,^{qq} Xiuqing Guo, PhD,^{g,i,rr} Pim van der Harst, MD, PhD,^{bb} Peter K. Joshi, PhD,^{aa} Mika Kähönen, MD, PhD,^{ss} Bryan Kestenbaum, MD, MS,^{tt} Maria F. Lima-Costa, MD, PhD,^{uu} Allan Linneberg, MD, PhD,^{pp,vv} Arie C. Maan, PhD,^{ww} Thomas Meitinger, MD,^{x,xx,yy} Sandosh Padmanabhan, MD, PhD,^{zz} Cristian Pattaro, PhD,^p Annette Peters, PhD,^{ww,aaa,bbb} Astrid Petersmann, MD,^{ccc} Peter Sever, MD,^{ddd} Mortiz F. Sinner, MD, PhD,^{w,x} Xia Shen, PhD,^{aa,eee,fff} Alice Stanton, MD,^{ggg} Konstantin Strauch, PhD,^{v,hhh} Elsayed Z. Soliman, MD,^{iii,jjj,kkk} Kirill V. Tarasov, MD, PhD,^{lll} Kent D. Taylor, PhD,^{g,i,rr} Chris H.L. Thio, MSc,^u André G. Uitterlinden, PhD,^{mmmm} Simona Vaccargiu, BS,ⁿⁿⁿ Melanie Waldenberger, PhD,^{x,aaa,ooo} Antonietta Robino, PhD,^m Adolfo Correa, MD,^{ppp} Francesco Cucca, PhD,^{qqq} Steven R. Cummings, MD,^o Marcus Dörr, MD,^{gg,rrr} Giorgia Grotto, PhD,^{mm,ij} Vilundur Gudnason, MD, PhD,^{hh,sss} Torben Hansen, MD, PhD,^e Susan R. Heckbert, MD, PhD,^{ttt} Christian R. Juhl, MD,^d Stefan Käb, MD,^{w,x} Terho Lehtimäki, MD, PhD,^q Yongmei Liu, MD, PhD,ⁱⁱⁱ Paulo A. Lotufo, MD, MPH, DPH,^{uuu} Colin N.A. Palmer, PhD,^{cc} Mario Pirastu, MD,ⁿⁿⁿ Peter P. Pramstaller, MD,^{p,vvv,www} Antonio Luiz P. Ribeiro, MD, PhD,^{xxx} Jerome I. Rotter, MD,^{g,i,rr} Nilesh J. Samani, MD,^{y,z} Harold Snieder, PhD,^u Tim D. Spector, FMEdSci,^r Bruno H. Stricker, MMed, PhD,^f Niek Verweij, PhD,^{bb} James F. Wilson, DPHIL,^{aa,yyy} James G. Wilson, MD,^{zzz} J. Wouter Jukema, MD, PhD,^{www} Andrew Tinker, MD, PhD,^{c,kk} Christopher H. Newton-Cheh, MD, PhD,^{aaaa,bbbb,cccc} Nona Sotoodehnia, MD, MPH,^{dddd} Dennis O. Mook-Kanamori, MD, PhD,^{eeee,ffff,*} Patricia B. Munroe, PhD,^{c,kk,*} Helen R. Warren, PhD,^{c,kk,*}

From the ^aDepartment of Internal Medicine, Section of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, the Netherlands; ^bBarts Heart Centre, St. Bartholomew's Hospital, London, United Kingdom; ^cClinical Pharmacology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom; ^dLaboratory of Experimental Cardiology, Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark; ^eNovo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; ^fDepartment of Epidemiology, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands; ^gInstitute for Translational Genomics and Population Sciences, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California; ^hDivision of Medical Genetics, Department of Pediatrics, Harbor-UCLA Medical Center, Torrance, California; ⁱDepartment of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California; ^jFaculty of Medicine and Clinical Hospital, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil; ^kCardiovascular Health Research Unit, Department of Medicine, and Department of Biostatistics, University of Washington, Seattle, Washington; ^lInstitute of Molecular Genetics, National Research Council of Italy, Pavia, Italy; ^mInstitute for Maternal and Child Health, IRCCS Burlo Garofolo, Trieste, Italy; ⁿTranslational Gerontology Branch, National Institute on Aging, National Institutes of Health, Baltimore, Maryland; ^oCalifornia Pacific Medical Center Research Institute, San Francisco, California; ^pEurac Research, Institute for Biomedicine, affiliated to the University of Lübeck, Bolzano, Italy; ^qDepartment of Clinical Chemistry, Fimlab Laboratories, Finnish Cardiovascular Research Center Tampere, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland; ^rDepartment of Twin Research and Genetic Epidemiology, King's College London, London, United Kingdom; ^sNational Institute for Health Research Biomedical Research Centre at Guy's and St. Thomas' Foundation Trust, London, United Kingdom; ^tDepartment of Data Science, University of Mississippi Medical Center, Jackson, Mississippi; ^uDepartment of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; ^vInstitute of Genetic Epidemiology, Helmholtz Zentrum München-German Research Center for Environmental Health, Neuherberg, Germany; ^wDepartment of Internal Medicine I (Cardiology), Hospital of the Ludwig-Maximilians-University Munich, Munich, Germany; ^xDZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany; ^yCardiovascular Research Centre, Glenfield Hospital, Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom;

ABSTRACT

BACKGROUND Subclinical changes on the electrocardiogram are risk factors for cardiovascular mortality. Recognition and knowledge of electrolyte associations in cardiac electrophysiology are based on only in vitro models and observations in patients with severe medical conditions.

OBJECTIVES This study sought to investigate associations between serum electrolyte concentrations and changes in cardiac electrophysiology in the general population.

METHODS Summary results collected from 153,014 individuals (54.4% women; mean age 55.1 ± 12.1 years) from 33 studies (of 5 ancestries) were meta-analyzed. Linear regression analyses examining associations between electrolyte concentrations (mmol/l of calcium, potassium, sodium, and magnesium), and electrocardiographic intervals (RR, QT, QRS, JT, and PR intervals) were performed. The study adjusted for potential confounders and also stratified by ancestry, sex, and use of antihypertensive drugs.

RESULTS Lower calcium was associated with longer QT intervals (-11.5 ms; 99.75% confidence interval [CI]: -13.7 to -9.3) and JT duration, with sex-specific effects. In contrast, higher magnesium was associated with longer QT intervals (7.2 ms; 99.75% CI: 1.3 to 13.1) and JT. Lower potassium was associated with longer QT intervals (-2.8 ms; 99.75% CI: -3.5 to -2.0), JT, QRS, and PR durations, but all potassium associations were driven by use of antihypertensive drugs. No physiologically relevant associations were observed for sodium or RR intervals.

CONCLUSIONS The study identified physiologically relevant associations between electrolytes and electrocardiographic intervals in a large-scale analysis combining cohorts from different settings. The results provide insights for further cardiac electrophysiology research and could potentially influence clinical practice, especially the association between calcium and QT duration, by which calcium levels at the bottom 2% of the population distribution led to clinically relevant QT prolongation by >5 m s .

²National Institute for Health Research Leicester Biomedical Research Centre, Glenfield Hospital, Leicester, United Kingdom; ^{aa}Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, Scotland; ^{bb}Department of Cardiology and Thorax Surgery, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; ^{cc}Division of Molecular and Clinical Medicine, Pat Macpherson Centre for Pharmacogenetics and Pharmacogenomics, Ninewells Hospital and Medical School, University of Dundee, Dundee, United Kingdom; ^{dd}Department of Pharmacy, COMSATS University Islamabad, Abbottabad, Pakistan; ^{ee}School of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, Brasil; ^{ff}Interfaculty Institute for Genetics and Functional Genomics, University of Greifswald, Greifswald, Germany; ^{gg}German Centre for Cardiovascular Research, partner site Greifswald, Greifswald, Germany; ^{hh}Icelandic Heart Association, Kópavogur, Iceland; ⁱⁱCardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, Washington; ^{jj}Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy; ^{kk}National Institute for Health Research Barts Cardiovascular Biomedical Research Centre, Queen Mary University of London, London, United Kingdom; ^{ll}Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom; ^{mmm}Department of Production, Research and Innovation, Region Zealand, Sorø, Denmark; ⁿⁿⁿHarvard Medical School, Boston, Massachusetts; ^{ooo}Department of Laboratory Medicine, Boston Children's Hospital, Boston, Massachusetts; ^{ppp}Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; ^{qqq}Department of Health Science and Technology, Aalborg University, Aalborg, Denmark; ^{rrr}Division of Genomic Outcomes, Department of Pediatrics, Harbor-UCLA Medical Center, Torrance, California; ^{sss}Department of Clinical Physiology, Tampere University Hospital, Finnish Cardiovascular Research Center-Tampere, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland; ^{ttt}Kidney Research Institute, University of Washington, Seattle, Washington; ^{uuu}Rene Rachou Research Institute, Oswaldo Cruz Foundation, Belo Horizonte, Brazil; ^{vvv}Center for Clinical Research and Prevention, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark; ^{www}Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands; ^{xxx}Institute of Human Genetics, Helmholtz Zentrum München-German Research Center for Environmental Health, Neuherberg, Germany; ^{yyy}Institute of Human Genetics, Technische Universität München, Munich, Germany; ^{zzz}Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom; ^{aaa}Institute of Epidemiology, Helmholtz Zentrum München-German Research Center for Environmental Health, Neuherberg, Germany; ^{bbb}German Center for Diabetes Research, Neuherberg, Germany; ^{ccc}Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany; ^{ddd}National Heart and Lung Institute, Imperial College London, London, United Kingdom; ^{eee}Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; ^{fff}Biostatistics Group, State Key Laboratory of

ABBREVIATIONS AND ACRONYMS

BMI = body mass index

BP = blood pressure

CI = confidence interval

ECG = electrocardiogram

HTN = hypertension

Q = quantile

QC = quality control

Disturbances in cardiac electrophysiology are well-recognized risk factors for cardiovascular morbidity and mortality. Prolonged QT intervals, as collective measures of ventricular depolarization and repolarization, and elevated resting heart rates have been consistently associated with adverse outcomes in epidemiological studies (1-4). Electrocardiogram (ECG) parameters correlate well with cardiac electrophysiology—in particular cardiac action potential measurements made in single cells or tissue preparations. The duration of the action potential

often mirrors the QT interval, while the maximum rate of depolarization determines conduction velocity and influences PR and QRS durations (5,6).

Extreme serum electrolyte concentrations, particularly for potassium and calcium, are well-known risk factors for repolarization disturbances, conduction abnormalities, and cardiac arrhythmias (7,8). The influence of electrolytes on cardiac action potentials can be studied unambiguously (9). For example, increases in extracellular calcium concentration shortens the action potential duration (10). However, the mechanisms are counterintuitive and not clearly explained. In a modeling study, in addition to increases in

Biocontrol, School of Life Sciences, Sun Yat-sen University, Guangzhou, China; ⁸⁸⁸Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland; ^{hh}Institute for Medical Information Processing, Biometry, and Epidemiology, Faculty of Medicine, Ludwig Maximilian University of Munich, Munich, Germany; ⁱⁱⁱDepartment of Epidemiology and Prevention, Division of Public Health Sciences, Wake Forest University, Winston-Salem, North Carolina; ^{jjj}Epidemiological Cardiology Research Center, Wake Forest School of Medicine, Winston-Salem, North Carolina; ^{kkk}Department of Internal Medicine, Cardiology Section, Wake Forest School of Medicine, Winston-Salem, North Carolina; ^{lll}Laboratory of Cardiovascular Science, National Institute on Aging, National Institutes of Health, Baltimore, Maryland; ^{mmmm}Human Genotyping Facility, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands; ⁿⁿⁿInstitute of Genetic and Biomedical Research, National Research Council of Italy, UOS of Sassari, Sassari, Italy; ^{ooo}Research Unit of Molecular Epidemiology, Helmholtz Zentrum München—German Research Center for Environmental Health, Neuherberg, Germany; ^{ppp}Department of Medicine, University of Mississippi Medical Center, Jackson, Mississippi; ^{qqq}Department of Biomedical Sciences, University of Sassari, Sassari, Italy; ^{rrr}Department of Internal Medicine B - Cardiology, Intensive Care, Pulmonary Medicine and Infectious Diseases, University Medicine Greifswald, Greifswald, Germany; ^{sss}Faculty of Medicine, University of Iceland, Reykjavik, Iceland; ^{ttt}Cardiovascular Health Research Unit and the Department of Epidemiology, University of Washington, Seattle, Washington; ^{uuu}Medical School and Center for Clinical and Epidemiologic Research, University of São Paulo, São Paulo, Brazil; ^{vvv}Department of Neurology, General Central Hospital, Bolzano, Italy; ^{www}Department of Neurology, University of Lübeck, Lübeck, Germany; ^{xxx}Hospital das Clínicas and School of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil; ^{yyy}MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh, United Kingdom; ^{zzz}Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, Mississippi; ^{aaaa}Cardiovascular Research Center, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts; ^{bbbb}Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts; ^{cccc}Center for Genomic Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts; ^{dddd}Cardiovascular Health Research Unit, Division of Cardiology, Departments of Medicine and Epidemiology, University of Washington, Seattle, Washington; ^{eeee}Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands; and the ^{ffff}Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, the Netherlands. *Drs. Noordam, Mook-Kanamori, Munroe, and Warren contributed equally to this work. Dr. Young was funded by the Medical Research Council (Grant code MR/R017468/1). Drs. Caulfield and Samani were National Institute of Health Senior Investigators. Drs. Tinker, Caulfield, Munroe, and Warren were supported by the National Institute for Health Research as part of the portfolio of translational research of the National Institute for Health Research Biomedical Research Centre at Barts and the London School of Medicine and Dentistry. Dr. Ribeiro is supported in part by grants from the CNPq (Bolsa de produtividade em pesquisa, 310679/2016-8), National Institute of Science and Technology for Health Technology Assessment (IATS/CNPq, project: 465518/2014-1), and FAPEMIG (Programa Pesquisador, Mineiro, PPM-00428-17). Dr. Lima-Costa is supported in part by a grant from the CNPq (Bolsa de produtividade em pesquisa, 303137/2014-2). Dr. Dominiczak was supported by the British Heart Foundation grant numbers RG/07/005/23633 and SP/08/005/25115, and by the European Union Ingenious HyperCare Consortium: Integrated Genomics, Clinical Research, and Care in Hypertension (grant number LSHM-C7-2006-037093). Dr. Wilson was supported by U54GM115428 from the National Institute of General Medical Sciences. Dr. Mook-Kanamori was supported by the Dutch Science Organization (ZonMW-VENI Grant 916.14.023). Dr. Joshi was supported by the Axa Research Fund. Dr. Verweij was supported by NWO VENI grant (016.186.125). Dr. Stricker was supported by grants from the Netherlands Organization for Health Research and Development (ZonMw) [Priority Medicines Elderly 113102005; and DoelmatigheidsOnderzoek 80-82500-98-10208]. Dr. Christofidou was supported by European Union's Horizon 2020 research and innovation programme under grant agreement No 733100. Dr. Tinker was funded by the British Heart Foundation grant RG/15/15/31742. Study-specific funding is presented in the supplementary materials. Dr. Caulfield is Chief Scientist for Genomics England, a UK government company. Dr. Sever has received research awards from Pfizer Inc.; and has served as a consultant for and received speaker fees from Amgen and Pfizer Inc. Dr. Newton-Cheh has received consulting fees from Novartis and Ironwood; and has received consulting fees and Advisory Board fees from GE Healthcare. Dr. Mook-Kanamori works as a part-time clinical research consultant at Metabolon, Inc. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Brian Olshansky, MD, served as Guest Associate Editor for this paper.

repolarizing potassium currents with increasing extracellular and intracellular calcium, it was also necessary to include increasing calcium dependent inactivation of the calcium current, to reproduce the observed relationship (11). A decrease in the sodium-calcium exchange may also contribute to the shortened action potential duration (12). In contrast, the effects of changes in action potential duration with extracellular magnesium are much smaller (13).

SEE PAGE 3132

Importantly, variation in serum electrolyte concentrations within normal ranges is associated with occurrence of cardiovascular disease (14). For example, risks for myocardial infarction increased by 20% for every 0.1-mmol/l rise in calcium (15). Increased hazard ratios for mortality have been observed at the extreme limits of the normal range for potassium (16). Studies evaluating electrolyte effects, however, are often cellular experiments or analyses in patient populations with multiple comorbidities. Such studies have difficulties in disentangling electrolyte versus direct disease effects. There is little information on associations between electrolytes and cardiac electrophysiology amongst relatively healthy individuals.

A direct link between serum electrolyte levels and cardiac physiology is indicated by genetic studies. Genome-wide association studies have identified multiple genes encoding electrolyte transporter and signaling proteins involved in cardiac physiology (17-19). For example, *KCNH2* encodes a subunit of the voltage-gated potassium channel hERG, and genetic variation in *KCNH2* can be associated with either a prolonged or shortened QT interval (17). Loss of function variants in *KCNH2* were identified in 30% of long QT syndrome cases, and gain of function mutations in *KCNH2* were identified in individuals with short QT syndrome (20,21).

Our hypothesis is that variation in serum electrolyte levels in the general population may alter cardiac electrophysiology. Identifying individuals at risk of electrophysiological disturbances may aid in prevention of cardiovascular disease and mortality. In this study, we performed a large-scale systematic analysis to investigate associations between serum electrolyte concentrations and electrocardiogram intervals within a healthy population free of severe cardiac abnormalities and including various ancestries.

METHODS

STUDY SETTING. Studies were eligible to join the project if participants had data on at least 1 electrolyte measured in serum and at least 1 ECG trait, both

measured at a similar time point. All contributing studies are described in the [Online Appendix](#) and in [Online Table 1](#).

All studies were approved by local Medical Ethical Committees in agreement with the declaration of Helsinki, and all participants provided written informed consent.

PARTICIPANT EXCLUSIONS. Individuals were excluded if they were <18 years of age or pregnant. For quality control (QC), outliers were excluded from the final electrolyte and ECG dataset (>5 SDs from the mean). Extreme RR intervals were also excluded (<500 or >1,500 ms). To minimize bias, and to exclude individuals with cardiovascular disease, we excluded individuals with atrial fibrillation, Wolff-Parkinson-White syndrome, second- or third-degree atrioventricular block, a history of myocardial infarction or heart failure, or a pacemaker, and anyone taking class I or class III blocking medication (ATC code: C01B).

EXPOSURE, OUTCOME AND COVARIATE DATA. Four electrolytes were considered as exposures: calcium, sodium, potassium, and magnesium, measured in serum in mmol/l. Five ECG measures were included in the analysis: QT, JT (as a measure of ventricular repolarization, where $JT = QT - QRS$), QRS, PR, and RR intervals, measured in milliseconds. Studies without ECG data contributed data only for RR interval, if heart rate was available from pulse measurements (by converting to RR using the formula: $RR [ms] = 60,000 / \text{heart rate [beats/min]}$). Participant age, sex, body mass index (BMI), creatinine level, diabetes mellitus status, and hypertension (HTN) status were included as covariates. Individuals were defined as being hypertensive if they met any 1 of the following criteria: 1) systolic blood pressure (BP) ≥ 140 mm Hg; 2) diastolic BP ≥ 90 mm Hg; or 3) taking BP-lowering medication (ATC codes: C02, C03, C04, C07, C08, C09). Sensitivity analyses were performed using new cutoffs for systolic and diastolic blood pressures from the American Heart Association/American College of Cardiology (22). Diabetes was defined according to: 1) a doctor's diagnosis of diabetes mellitus; 2) a fasting glucose concentration >6.9 mmol/l; or 3) taking any glucose-lowering medication (ATC code: A10), which is a generally accepted definition for harmonization across cohorts from different countries (23). Serum creatinine concentration levels were measured in $\mu\text{mol/l}$ and were log-transformed within all models.

STUDY-LEVEL STATISTICAL ANALYSES. A centrally written script using R statistical software (R Foundation for Statistical Computing, Vienna, Austria) was provided to each participating study, and the generated output files were submitted centrally

(which included study characteristics, histograms of variable distributions for QC, and summary statistics of regression analysis results), so that all studies ran identical analyses according to a harmonized protocol. Each study contributed to as many different models as possible, based on available data on exposures, outcomes, and covariates. Analyses were performed for each ECG trait separately, to allow for differing sample sizes for each combination of ECG trait and electrolyte. For studies with individuals of different ancestries (notably, the CHS [Cardiovascular Health Study], HABC [Health, Aging, and Body Composition Study], and MESA [Multi-Ethnic Study of Atherosclerosis]), analyses were stratified by each ancestry.

As our primary analyses, we performed linear regression analyses regressing each ECG trait on each electrolyte, adjusting for sex and age. Except for analyses on RR interval itself, all analyses were statistically adjusted for RR interval which is generally a more suitable heart-rate correction method than other methods such as Bazett (24,25). Our cohorts essentially had unrelated individuals except for the CHRIS (Cooperative Health Research in South Tirol), MICROS (Microisolates in South Tirol), ORCADES (Orkney Complex Disease Study), and VIKING (Viking Health Study - Shetland) studies, which used mixed models to correct for relatedness between study participants. By analyzing all paired combinations of the 5 ECG traits and 4 electrolytes, there were 20 primary linear regression analyses in all participants. For each electrolyte-ECG trait association, we assessed the role of confounding by adding—one by one—the other covariates to the statistical models (BMI [present in all subsequent adjusted models], diabetes mellitus status, HTN status, and creatinine). Our fully adjusted model using all covariates contained data from only the studies with all covariates available.

We also performed analyses stratified by sex, use of antihypertensive drugs (+ digoxin), and HTN status. Use of antihypertensive drugs (+ digoxin) was defined according to ATC codes (C01AA05 for digoxin; or C02, C03, C04, C07, C08, C09 for any BP-lowering medication). Note that individuals would belong to the drug-users subgroup but not to the HTN-only subgroup if they were taking only digoxin. Similarly, participants would belong to the HTN-only subgroup but not in the drug-users subgroup if they were untreated hypertensives. Due to the overlap with HTN as a covariate in the adjusted submodels, these subgroup analyses stratified by drug use and by HTN status were performed for only the 2 basic models adjusted for age, sex (and RR interval), and additionally for BMI.

Finally, to investigate the trend of associations across electrolyte levels and across the population distribution for the main electrolyte-ECG associations, we performed analyses stratified by quintiles of the electrolyte concentrations. The 5 quintiles were generated from the distribution of each electrolyte: Q1 to Q5. Pairwise comparison analyses were performed, using the minimally adjusted model (adjusted only for age and sex), with the middle quintile (Q3) as reference.

META-ANALYSES. After QC of the received summary statistics data, fixed-effects inverse variance-weighted meta-analyses were performed centrally using the “rmeta” CRAN package in R statistical software, pooling together the beta effect estimates and standard errors from all studies. As further QC, before the meta-analyses, we excluded any analysis model results from studies that were estimated in small sample sizes (<100 individuals). Two sets of meta-analyses were performed: an all-ancestry meta-analysis and 5 ancestry-stratified meta-analyses.

Due to the 20 different ECG-electrolyte associations, we corrected for multiple testing by the Bonferroni method and present results with 99.75% confidence intervals (CIs). For any significant association from our primary analysis in the minimally adjusted model, we used the following sequential strategy for reporting results: 1) significant associations from the minimally adjusted model were checked for robustness to covariate adjustment, by comparing them with results from the fully adjusted model; 2) the effect sizes of the robust associations were evaluated for their physiological importance and the plots from the quintile analyses were checked for clear linear trends supporting association results; and 3) associations meeting these requirements were reported and considered further within subgroup analyses by sex, drug use, and HTN status.

POST-META-ANALYSIS INTERACTION ANALYSES. Based on the coefficients from the meta-analyses from the models stratified by sex, drug use, and HTN status, we additionally tested for evidence of effect modification on a multiplicative scale, using the methodology that has been previously described by Altman and Bland (26). Two-sided p values for interaction <0.05 were considered significant.

RESULTS

CHARACTERISTICS OF THE STUDY POPULATION. In the present study, we used data from a total of 38 study groups from 33 cohorts representing 5 different ancestries: European ($n_{\max} = 129,169$ from 30 studies); African-American ($n_{\max} = 7,693$ from 4

TABLE 1 Pooled Characteristics of the Study Populations

	Total	Sex		Drug Use		
		Male	Female	Users	Nonusers	
Age, yrs	153,014	55.1 ± 12.1	55.5 ± 11.9	54.7 ± 12.2	59.0 ± 9.9	51.5 ± 11.6
Body mass index, kg/m ²	152,481	27.3 ± 4.8	27.5 ± 4.2	27.1 ± 5.3	27.8 ± 5.0	26.2 ± 4.6
Creatinine, μmol/l	151,691	81.3 ± 22.4	91.1 ± 22.9	73.2 ± 18.6	–	–
Electrolytes*						
Calcium, mmol/l	90,575	2.33 ± 0.11	2.33 ± 0.11	2.33 ± 0.11	2.36 ± 0.11	2.32 ± 0.11
Potassium, mmol/l	129,464	4.23 ± 0.37	4.27 ± 0.37	4.19 ± 0.36	4.20 ± 0.43	4.23 ± 0.35
Sodium, mmol/l	125,760	141.00 ± 2.70	141.00 ± 2.60	141.00 ± 2.70	141.00 ± 2.80	141.00 ± 2.60
Magnesium, mmol/l	42,720	0.83 ± 0.08	0.83 ± 0.08	0.82 ± 0.08	0.83 ± 0.08	0.83 ± 0.07
ECG measures						
RR interval, ms	153,014	917.0 ± 148.0	935.0 ± 155.0	903.0 ± 139.0	872.0 ± 148.0	903.0 ± 144.0
QT interval, ms	125,104	399.0 ± 28.7	403.0 ± 29.3	400.0 ± 28.1	388.0 ± 30.0	395.0 ± 27.3
QRS interval, ms	123,695	92.7 ± 12.9	97.8 ± 12.9	90.3 ± 11.6	90.3 ± 13.9	91.8 ± 12.1
JT interval, ms	121,355	311.0 ± 28.4	304.0 ± 28.3	316.0 ± 27.4	297.0 ± 29.4	303.0 ± 27.2
PR interval, ms	124,078	159.0 ± 24.3	164.0 ± 24.4	158.0 ± 23.5	156.0 ± 25.3	156.0 ± 22.9

Values are n or mean ± SD. Study-level characteristics were collected from each study, with summary descriptive statistics for all continuous variables used within the analysis models: covariates; electrolytes and electrocardiogram (ECG) measures. These characteristics were then pooled together centrally across all studies. Drug use is defined as the use of antihypertensive drugs + digoxin. *Due to the alternative analysis pipeline used in the ORCADES (Orkney Complex Disease Study) and VIKING (Viking Health Study - Shetland) studies, these studies were not able to provide means and standard deviations for the electrolytes.

studies); “mixed” ancestry from Brazil ($n_{\max} = 14,612$ from 2 studies: the BAMBUI [Bambui (Brazil) Cohort Study of Ageing] and ELSA-Brasil [Longitudinal Study of Adult Health]); Asian ($n_{\max} = 555$ from 1 study: the MESA study); and Hispanic/Latino ($n_{\max} = 985$ from 1 study: the MESA study). Overall, we collected data from a total of 153,014 individuals (45.6% men) (Table 1). Mean age was 55.1 ± 12.1 years, and individuals were on average slightly overweight (mean BMI 27.3 ± 4.8 kg/m²). Serum electrolyte levels were distributed similarly among men and women and among drug users and nonusers. Study-specific characteristics are presented in Online Tables 1 to 3.

ASSOCIATION BETWEEN SERUM ELECTROLYTE CONCENTRATIONS AND ECG PARAMETERS.

After observing no substantial heterogeneity between the different ancestry groups from inspection of forest plots (Online Figure 1), the all-ancestry meta-analyses were used as the primary analysis results, to maximize sample size. Of the 20 main electrolyte-ECG trait associations, we found evidence for 14 associations between a serum electrolyte concentration and an ECG trait (Table 2, Figure 1). There was no consistent heterogeneity observed between the participating studies from inspection of cohort-level forest plots (Online Figure 2).

High calcium was associated with shorter QT (-11.5 [99.75% CI: -13.7 to -9.3] ms per mmol/l) and JT (-15.6 [99.75% CI: -18.3 to -12.9] ms per mmol/l) intervals, and effect sizes increased in the fully adjusted model (Table 2), due to adjustment for HTN and diabetes status. In contrast, high magnesium was associated

with longer QT (7.2 [99.75% CI: $1.3, 13.1$] ms/mmol/l) and JT (9.9 [99.75% CI: $4.1, 15.6$] ms per mmol/l) intervals, with similar results observed in the fully adjusted model (Table 2). High potassium was associated with shorter QT (-2.8 [99.75% CI: -3.5 to -2.0] ms per mmol/l), QRS (-1.6 [99.75% CI: -1.9 to -1.3] ms per mmol/l), JT (-1.0 [99.75% CI: -1.8 to -0.3] ms per mmol/l), and PR (-1.7 [99.75% CI: -2.4 to -1.1] ms per mmol/l) intervals, also with similar effect sizes in the fully adjusted model (Table 2). There were clear trends for the calcium, magnesium, and potassium associations when study populations were stratified by quintiles, indicating support for the associations across the population distribution of electrolyte levels (Online Figure 3).

High sodium was associated with longer QRS (0.1 [99.75% CI: 0.0 to 0.1] ms per mmol/l) and JT (0.2 [99.75% CI: 0.1 to 0.3] ms per mmol/l) intervals, but sodium was associated with only QRS interval in the fully adjusted model, suggesting an influence of confounding, which was found to be from HTN and diabetes (Table 2, Figure 1). Moreover, the small effect sizes for sodium would not be viewed as physiologically relevant (0.1 - to 0.2 -ms increase in QRS interval per 1-mmol/l increase in sodium), and there was no meaningful trend in the quintile analyses to support an association (Online Figure 3).

In general, all electrolytes examined were associated with RR interval, and results were similar in the fully adjusted model (Table 2). Although associations with RR intervals reached statistical significance, effect sizes were very small (e.g., 64.1-ms change in RR per 1-mmol/l increase in magnesium). Such changes

TABLE 2 Association Between Serum Electrolyte Concentrations and ECG Measures in the General Population

	Minimally Adjusted Model			Fully Adjusted Model for All Potential Confounders		
	N	Beta	99.75% CI	N	Beta	99.75% CI
Calcium						
RR interval	94,264 (33)	-21.1	-33.6 to -8.7	77,520 (26)	-32.1	-46.6 to -17.5
QT interval	77,479 (31)	-11.5	-13.7 to -9.3	62,874 (25)	-22.3	-25.7 to -18.9
QRS interval	77,471 (31)	0.45	-0.6 to 1.5	62,869 (25)	0.4	-1.0 to 1.8
JT interval	75,222 (29)	-15.6	-18.3 to -12.9	62,342 (24)	-22.7	-26.0 to -19.4
PR interval	76,834 (30)	1.4	-0.7 to 3.6	62,267 (24)	1.2	-1.5 to 3.9
Magnesium						
RR interval	44,682 (16)	64.1	37.5 to 90.7	36,940 (13)	39.8	10.6 to 69.0
QT interval	36,165 (14)	7.2	1.3 to 13.1	30,509 (12)	6.4	0.0 to 12.8
QRS interval	36,138 (14)	-1.0	-3.6 to 1.5	30,509 (12)	-0.3	-3.0 to 2.5
JT interval	36,165 (14)	9.9	4.1 to 15.6	30,529 (12)	7.9	1.6 to 14.2
PR interval	35,956 (14)	2.5	-2.2 to 7.2	30,355 (12)	3.3	-1.9 to 8.5
Potassium						
RR interval	126,528 (29)	13.9	10.6 to 17.3	87,875 (23)	12.4	8.5 to 16.3
QT interval	98,669 (26)	-2.8	-3.5 to -2.0	66,941 (22)	-2.8	-3.6 to -1.9
QRS interval	97,283 (26)	-1.6	-1.9 to -1.3	65,576 (22)	-1.3	-1.7 to -1.0
JT interval	96,656 (25)	-1.0	-1.8 to -0.3	64,995 (21)	-1.2	-2.1 to -0.3
PR interval	97,725 (25)	-1.7	-2.4 to -1.1	66,312 (21)	-1.6	-2.3 to -0.8
Sodium						
RR interval	122,732 (28)	2.4	1.9 to 2.9	84,116 (22)	1.3	0.8 to 1.8
QT interval	94,787 (25)	0.0	-0.1 to 0.1	63,182 (21)	0.1	-0.1 to 0.2
QRS interval	93,483 (25)	0.1	0.0 to 0.1	61,815 (21)	0.1	0.0 to 0.1
JT interval	92,857 (24)	0.2	0.1 to 0.3	61,236 (20)	0.0	-0.1 to 0.1
PR interval	93,914 (24)	-0.1	-0.2 to 0.0	62,541 (20)	0.0	-0.2 to 0.1

N is the number of individuals included in the analyses with the number of studies contributing to the analysis in parentheses. Beta is the effect estimate from the linear regression model. The Minimally Adjusted Model included adjustment for age, sex, RR interval, and cohort-specific covariates. The Fully Adjusted Model, in the cohorts with data on all covariates available, was additionally adjusted for body mass index, diabetes mellitus status, hypertension status, and natural log of serum creatinine concentration. The beta effect results presented are the changes in electrocardiogram (ECG) measure in milliseconds per 1-mmol/l increase in electrolyte concentration. A 2-sided p value was considered statistically significant.
CI = confidence interval.

would not be viewed as physiologically important, considering the population distributions of electrolyte levels and RR durations. Furthermore, the electrolyte-RR interval associations did not show clear trends when electrolyte levels were stratified by quintiles (Online Figure 3).

Hence, none of the associations for RR interval or sodium were considered further. Therefore, the 8 key associations of interest are: calcium and magnesium with QT and JT intervals and potassium with 4 ECG traits (QT, QRS, JT, and PR interval).

SUBGROUP ANALYSES. Based on the 8 electrolyte-ECG trait associations observed in the main analysis, we additionally stratified by sex, drug use, or HTN status. With the minimally adjusted model, we found evidence of sex-specific associations (p value interaction <0.05) for only calcium and QT (P_{interaction} = 0.008) and JT (P_{interaction} = 0.008) intervals (Online Table 4, Figure 2), with stronger


associations in women than in men. Specifically, per mmol/l increase, calcium was associated with 8.8 (99.75% CI: -12.1 to -8.0) ms and 12.1 (99.75% CI: -16.3 to -8.0) ms shorter JT intervals in men, compared with 12.6 (99.75% CI: -15.5 to -9.8) and 16.9 (99.75% CI: -20.4 to -13.4) ms, respectively, for women.

When stratified according to drug use, non-drug users had attenuated associations between potassium and QT, QRS, JT, and PR intervals (Online Table 5, Figure 3). For each mmol/l increase in potassium, QT intervals were -5.5 (99.75% CI: -6.9 to -4.2) ms shorter in drug-users, but only -0.9 (99.75% CI: -1.8 to 0.0) ms shorter in nonusers, in the minimally adjusted model (p_{interaction} <0.001). Similar results were observed for JT intervals, and to a lesser extent for PR and QRS intervals. Attenuation also occurred for calcium, but to a much lesser extent, and associations were still observed in nonusers. An increase of 1 mmol/l of calcium was associated with a -16.1 (99.75% CI: -21.1 to -10.9) ms shorter QT interval in drug users, but with a -11.1 (99.75% CI: -13.4 to -7.7) ms shorter QT interval in nonusers (p value for interaction = 0.007). Results were similar when we stratified by HTN status (drug use/140/90 mm Hg), but the differences in associations were usually less pronounced than when we stratified by drug use (Online Table 6), particularly with lower hypertension cutoffs (drug use/130/90 mm Hg or drug use/120/80 mm Hg) in the analyses on potassium (Online Table 7). All subgroup results remained comparable in the adjusted model.

DISCUSSION

We investigated associations between serum electrolyte levels and measures of cardiac electrophysiology in a large-scale population-based meta-analysis. We observed 8 associations that had cardiac electrophysiological relevance. After full adjustment for considered confounding factors, we found that higher calcium levels were associated with shorter QT and JT intervals, and magnesium with longer QT and JT intervals, reflecting shortened and prolonged ventricular repolarization, respectively. Interestingly, the relationship between shortened ventricular repolarization and calcium was stronger in women. Higher potassium levels were associated with shorter QT, QRS, JT, and PR intervals. However, associations with potassium were observed specifically in drug users (mainly antihypertensive drugs) and hypertensive individuals. The associations with potassium are therefore assumed to be related to antihypertension treatment. No physiologically relevant associations were observed for sodium.

FIGURE 1 Associations Between Serum Electrolyte Concentrations and Measures on the Electrocardiogram




Beta effect results can be interpreted as the difference in milliseconds of the electrocardiogram (ECG) measure per 1-SD increase in serum electrolyte concentration. **Red bars** reflect positive associations, **blue bars** reflect negative associations. The **intensity of the color** refers to the precision of the association. Analyses in model 1 were adjusted for age, sex, and RR interval (minimally adjusted model). Analyses in model 4 were adjusted for age, sex, RR interval, body mass index, hypertension status, diabetes mellitus status, and natural log of serum creatinine concentration (fully adjusted model). A 2-sided p value <0.0025 according to Bonferroni correction was considered statistically significant. Please note: RR interval associations are not shown.

Although all 4 electrolytes were significantly associated with RR interval, none of the associations was viewed as clinically or electrophysiologically important. Collectively, our findings from a collection of (population-based) cohort studies of different

settings contribute to understanding the role of electrolytes in cardiac electrophysiology in the general population.

Lower calcium levels were robustly associated with longer QT and JT intervals—but not QRS

FIGURE 2 Sex-Specific Association Between Serum Calcium and QT and JT Intervals



Results are presented as the beta effect sizes with 99.75% confidence intervals (in milliseconds per mmol/L increase in calcium concentration), for men (circles) and women (squares) separately. The minimally adjusted model included covariate adjustment for age, sex, RR interval, and cohort-specific covariates. The fully adjusted model additionally included body mass index, diabetes mellitus status, hypertension status, and natural log of serum creatinine concentration. P-int = p value from the interaction analysis.

duration—across different subgroups, reflecting ventricular repolarization primarily. Biologically, calcium is stored in large amounts in the sarcoplasm reticulum, ready to be released for cardiac muscle contraction initiated by an inward L-type calcium current.

Based on the effect sizes in the fully adjusted model, we estimated the proportion of the general population that has clinically significant changes in the QT duration (which has clinical cutoff values) (Central Illustration). According to our data, 2% of the general population (irrespective of sex) have a calcium concentration that prolongs the QT interval by 5 ms or more. The U.S. Food and Drug Administration uses 5 ms as the threshold level for regulatory concern following a “thorough QT/QTc study” in healthy volunteers—a required part of the evaluation of new treatment compounds before market launch (27). The Food and Drug Administration practices potentially highlight the clinical importance of our findings and suggest the possible usefulness of ECG assessment in patients with low calcium levels, to prevent arrhythmic events, particularly in the presence of other interacting risk factors for ventricular repolarization prolongation.


Our findings may be more clinically relevant to women, due to the larger observed effects, although we are unable to explain the sex-specific differences. To the best of our knowledge, there are no reports on

sex-specific expression profiles of calcium channels or receptors in cardiac myocytes. Interestingly, 17 β -estradiol—an estrogen hormone—inhibits calcium channels (28–30). However, considering the mean age (55 years), women in our study population are likely to be mostly postmenopausal, with significantly lower estradiol levels. More research is therefore required to elucidate the cause of the sex-specific observations.

A higher magnesium concentration was associated with longer QT and JT intervals. However, magnesium effect sizes were fairly small (Central Illustration). Nevertheless, our results suggest a biological role for magnesium in ventricular repolarization. In animal tissue samples, the effect of magnesium on transmembrane potentials of cardiac myocytes is also less substantial, in contrast to other electrolytes (13). Clinically, previous research suggested a linear relationship between magnesium and coronary heart disease mortality, where a 0.1-mmol/L increase in serum magnesium—even within normal ranges—was associated with decreased risk (31). Our associations for magnesium in a large-scale study represent novel contributions, considering the fewer published reports on magnesium, compared with other electrolytes.

We observed shorter PR, QRS, QT, and JT intervals with increasing potassium. The effects of increasing

FIGURE 3 Associations for Potassium and Calcium Stratified by Drug Use




Results are presented as the beta effect sizes with 99.75% confidence intervals (in milliseconds per mmol/L increase in calcium or potassium concentration), for drug use (circles) and non-drug use (squares) separately. The minimally adjusted model included covariate adjustment for age, sex, RR interval, and cohort-specific covariates. The fully adjusted model additionally included body mass index, diabetes mellitus status, hypertension status, and natural log of serum creatinine concentration. P-int = p value from the interaction analysis.

potassium concentrations are recognized to be biphasic. Within the physiological range, increasing extracellular potassium causes a paradoxical increase in outward current mediated by hERG channels which initially shortens the action potential and stabilizes the resting membrane potential (32). Combined with an increase in the velocity of phase 3 of the action potential, this manifests as shortening of the QT interval and peaking of the T-wave (33,34). When potassium concentrations reach those associated with

clinically defined hyperkalemia, the resting membrane potential decreases, reducing the upstroke velocity of the action potential thus delaying interventricular conduction (33). This results in the classical ECG characteristics of hyperkalemia such as a prolonged QRS duration.

Interestingly, potassium effects were significantly greater in individuals on antihypertensive medication, with prolongation of the QT interval of 5 ms or more in ~4% of participants (Figure 4). The greater

CENTRAL ILLUSTRATION Main Electrolyte-Electrocardiogram Findings in the Unselected Population

Noordam, R. et al. *J Am Coll Cardiol.* 2019;73(24):3118-31.

The main findings in our study of unselected individuals. Low calcium, high magnesium, and high potassium were particularly associated with prolonged ventricular repolarization (longer QT and JT intervals). Sodium levels were not associated with any of the considered measures from the electrocardiogram.


effect of potassium on ECG intervals in individuals taking antihypertensive medication may be explained by direct and indirect drug effects. In vitro studies have demonstrated inhibitory effects of beta-blockers on hERG channels, through direct blocking of the channel. Angiotensin receptor blockers impede currents carried by hKv1.5, KvLQT1, KCNQ1, and hERG(Ikr) subunits (35,36). Overexpression of angiotensin II type 1 receptors in mouse ventricular myocytes decreases myocyte potassium currents, lengthens action potential duration, and significantly prolongs QT intervals (even after adjustment for QRS duration) (37).

There are few reports on long-term effects of antihypertensive medication on ventricular repolarization in humans. Three small studies of individuals with left ventricular hypertrophy related to hypertension showed improvement in echocardiographic and ECG findings of hypertrophy—with shortening of the QT interval—following use of an angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, or beta-blocker (atenolol) (38-40). These ECG

changes may be due to ventricular remodeling, or also to changes in autonomic tone. For example, the QT/RR slope relationship can be influenced by autonomic tone, which could augment effects of serum potassium on ECG intervals (41), as suggested by our study. Our study did not have complete information on the exact medications used (antihypertensive agents or other drugs that may affect ECG intervals). However, individuals taking class I or III antiarrhythmics were excluded meaning that the number of individuals taking digoxin is expected to be very low and unlikely to impact results. Furthermore, indications for taking these drugs may differ among individuals, and the various underlying etiologies may influence ECG characteristics.

Historically, an influence of circulating electrolytes on the ECG has been known for ~100 years. For example, 20 years after Einthoven reported his string galvanometer in 1903 (42), Carter and Andrus (43) observed long QT durations in infants with tetany from hypocalcemia. The QT duration decreased when the tetanic infants were given oral calcium. Prolonged

FIGURE 4 Differences in Effects of Electrolytes on QT Durations, for Different Percentiles of Electrolyte Levels



For each percentile point, the graphs indicate the difference between the beta estimate at that percentile and the beta estimate at the 50th percentile (in milliseconds of QT interval per mmol/L increase in calcium). For plots **A to C**, the estimated effects are calculated according to the fully adjusted model. For plots **D and E** from subgroup analyses, the estimated effects are calculated according to the model adjusted for age, sex, RR interval, and body mass index. The **shading** represents the 95% confidence interval.

QT intervals were seen with low potassium levels as early as 1950 (44). Several other reports on electrolytes and ECGs followed shortly thereafter (34,45-49). However, electrolyte effects have not been well described apart from patient populations. For example, electrolyte effects were not analyzed in a study of 32,949 normal ECGs at Vanderbilt University (in subjects without heart disease, medications that affect ECGs, or abnormal electrolytes) (50). Our report represents the first large-scale ECG analysis in relation to electrolyte levels in the general population.

STUDY STRENGTHS AND LIMITATIONS. A major strength is that our study is sufficiently powered to investigate associations between serum electrolyte levels and cardiac electrophysiology measures. The large collection of (population-based) cohorts in this study minimizes the risk of reporting cohort-specific (false positive) results. Also, all data were analyzed by use of a standardized protocol, to minimize differences in analyses among the individual studies. This would be a useful strategy to adopt for future analyses incorporating data from multiple different cohorts, although meta-analyses techniques should always be performed and the assessment of nonlinearity remains difficult. Our analyses of different ancestries did not show major heterogeneity in our findings, and confounders were taken into consideration (where possible). However, the list of confounders considered was limited by access to individual level data available among the participating studies. The limitations in our study were that we were not able to study dynamic interrelations among all serum electrolytes jointly in relation to ECG intervals because only a few cohorts had data on all 4 electrolytes. This would be an interesting area for follow-up in a subset of the cohorts. Calcium is usually bound to albumin, and low calcium can be caused by low albumin levels. However, we believe albumin plays a negligible role in the present study because low albumin levels are rare in the general population. Although the observational nature of our study limits causal inferences, biological evidence supporting our results favors an interpretation the electrolyte-ECG interval associations are causal. Finally, we stratified according to use of any antihypertensive treatment overall, rather than to the use of specific

antihypertensive drug classes as this information was not available. Possible alterations in potassium effects due to different antihypertensive drugs is an area to be explored in future studies.

CONCLUSIONS

Within our large-scale study, we identified multiple electrolyte-ECG associations relevant to ventricular repolarization, involving calcium, magnesium and potassium, although causality has yet to be determined. Regarding calcium and ventricular repolarization, a subgroup of the general population has an increase in QT interval that may be medically relevant, based on the effect sizes observed. Further research is necessary to improve our understanding of the underlying (causal) mechanisms involved.

ADDRESS FOR CORRESPONDENCE: Dr. Raymond Noordam, Department of Internal Medicine, Section of Gerontology and Geriatrics, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, the Netherlands. E-mail: r.noordam@lumc.nl. Twitter: [@drRNoordam](https://twitter.com/drRNoordam), [@lumc](https://twitter.com/lumc). OR Dr. Patricia B. Munroe, Department of Clinical Pharmacology, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ, United Kingdom. E-mail: p.b.munroe@qmul.ac.uk. Twitter: [@QMULBartsTheLon](https://twitter.com/QMULBartsTheLon), [@munroe_patsy](https://twitter.com/munroe_patsy).

PERSPECTIVES

COMPETENCY IN MEDICAL KNOWLEDGE: Low blood calcium levels prolong ventricular repolarization and lengthen the QT and JT intervals not only in patients with acute medical conditions but also in the general population.

TRANSLATIONAL OUTLOOK: Future studies should examine the mechanistic links underlying the association between ionized blood calcium concentration and myocardial repolarization and investigate whether therapy guided by periodic blood calcium measurements can prevent cardiovascular events.

REFERENCES

1. Nanchen D, Leening MJ, Locatelli I, et al. Resting heart rate and the risk of heart failure in healthy adults: the Rotterdam Study. *Circ Heart Fail* 2013;6:403-10.
2. Straus SM, Kors JA, De Bruin ML, et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. *J Am Coll Cardiol* 2006;47:362-7.
3. Kannel WB, Kannel C, Paffenbarger RS Jr., Cupples LA. Heart rate and cardiovascular mortality: the Framingham Study. *Am Heart J* 1987; 113:1489-94.

4. Saxena A, Minton D, Lee DC, et al. Protective role of resting heart rate on all-cause and cardiovascular disease mortality. *Mayo Clin Proc* 2013; 88:1420-6.
5. Finlay M, Harmer SC, Tinker A. The control of cardiac ventricular excitability by autonomic pathways. *Pharmacol Ther* 2017;174:97-111.
6. King JH, Huang CL, Fraser JA. Determinants of myocardial conduction velocity: implications for arrhythmogenesis. *Front Physiol* 2013;4:154.
7. Soar J, Perkins GD, Abbas G, et al. European Resuscitation Council Guidelines for Resuscitation 2010 Section 8. Cardiac arrest in special circumstances: Electrolyte abnormalities, poisoning, drowning, accidental hypothermia, hyperthermia, asthma, anaphylaxis, cardiac surgery, trauma, pregnancy, electrocution. *Resuscitation* 2010;81:1400-33.
8. Levis JT. ECG diagnosis: hypokalemia. *Perm J* 2012;16:57.
9. El-Sherif N, Turitto G. Electrolyte disorders and arrhythmogenesis. *Cardiol J* 2011;18:233-45.
10. Kass RS, Tsien RW. Control of action potential duration by calcium ions in cardiac Purkinje fibers. *J Gen Physiol* 1976;67:599-617.
11. Grandi E, Pasqualini FS, Pes C, Corsi C, Zaza A, Severi S. Theoretical investigation of action potential duration dependence on extracellular Ca²⁺ in human cardiomyocytes. *J Mol Cell Cardiol* 2009;46:332-42.
12. Leitch SP, Brown HF. Effect of raised extracellular calcium on characteristics of the guinea-pig ventricular action potential. *J Mol Cell Cardiol* 1996;28:541-51.
13. Hoffman BF, Suckling EE. Effect of several cations on transmembrane potentials of cardiac muscle. *Am J Physiol* 1956;186:317-24.
14. Wagner S, Maier LS, Bers DM. Role of sodium and calcium dysregulation in tachyarrhythmias in sudden cardiac death. *Circ Res* 2015;116:1956-70.
15. Jorde R, Sundsfjord J, Fitzgerald P, Bonaa KH. Serum calcium and cardiovascular risk factors and diseases: the Tromso study. *Hypertension* 1999; 34:484-90.
16. Chen Y, Sang Y, Ballew SH, et al. Race, serum potassium, and associations with ESRD and mortality. *Am J Kidney Dis* 2017;70:244-51.
17. Arking DE, Pulit SL, Crotti L, et al. Genetic association study of QT interval highlights role for calcium signaling pathways in myocardial repolarization. *Nat Genet* 2014;46:826-36.
18. den Hoed M, Eijgelsheim M, Esko T, et al. Identification of heart rate-associated loci and their effects on cardiac conduction and rhythm disorders. *Nat Genet* 2013;45:621-31.
19. van der Harst P, van Setten J, Verweij N, et al. 52 Genetic loci influencing myocardial mass. *J Am Coll Cardiol* 2016;68:1435-48.
20. Tester DJ, Ackerman MJ. Genetics of long QT syndrome. *Methodist DeBakey Cardiovasc J* 2014; 10:29-33.
21. Patel C, Yan GX, Antzelevitch C. Short QT syndrome: from bench to bedside. *Circ Arrhythm Electrophysiol* 2010;3:401-7.
22. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APHA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol* 2018;71:e127-248.
23. Mahajan A, Taliun D, Thurner M, et al. Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. *Nat Genet* 2018; 50:1505-13.
24. Rautaharju PM, Surawicz B, Gettes LS, et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. *J Am Coll Cardiol* 2009;53:982-91.
25. Indik JH, Pearson EC, Fried K, Woosley RL. Bazett and Fridericia QT correction formulas interfere with measurement of drug-induced changes in QT interval. *Heart Rhythm* 2006;3:1003-7.
26. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. *BMJ* 2003; 326:219.
27. E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Available at: <https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073153.pdf>. Accessed August 31, 2018.
28. Johnson BD, Zheng W, Korach KS, Scheuer T, Catterall WA, Rubanyi GM. Increased expression of the cardiac L-type calcium channel in estrogen receptor-deficient mice. *J Gen Physiol* 1997;110: 135-40.
29. Marni F, Wang Y, Morishima M, et al. 17 beta-estradiol modulates expression of low-voltage-activated Ca(V)3.2 T-type calcium channel via extracellularly regulated kinase pathway in cardiomyocytes. *Endocrinology* 2009;150:879-88.
30. Nakajima T, Iwasawa K, Oonuma H, et al. Antiarrhythmic effect and its underlying ionic mechanism of 17beta-estradiol in cardiac myocytes. *Br J Pharmacol* 1999;127:429-40.
31. Kieboom BC, Niemeijer MN, Leening MJ, et al. Serum magnesium and the risk of death from coronary heart disease and sudden cardiac death. *J Am Heart Assoc* 2016;5:e002707.
32. Shaw RM, Rudy Y. Electrophysiologic effects of acute myocardial ischemia. A mechanistic investigation of action potential conduction and conduction failure. *Circ Res* 1997;80:124-38.
33. Weiss JN, Qu Z, Shivkumar K. Electrophysiology of hypokalemia and hyperkalemia. *Circ Arrhythm Electrophysiol* 2017;10:e004667.
34. Surawicz B. Relationship between electrocardiogram and electrolytes. *Am Heart J* 1967;73: 814-34.
35. Kawakami K, Nagatomo T, Abe H, et al. Comparison of HERG channel blocking effects of various beta-blockers- implication for clinical strategy. *Br J Pharmacol* 2006;147:642-52.
36. Ehrlich JR, Hohnloser SH, Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. *Eur Heart J* 2006;27:512-7.
37. Rivard K, Paradis P, Nemer M, Fiset C. Cardiac-specific overexpression of the human type 1 angiotensin II receptor causes delayed repolarization. *Cardiovasc Res* 2008;78:53-62.
38. Malmqvist K, Kahan T, Edner M, Bergfeldt L. Cardiac repolarization and its relation to ventricular geometry and rate in reverse remodelling during antihypertensive therapy with irbesartan or atenolol: results from the SILVHIA study. *J Hum Hypertens* 2007;21:956-65.
39. Oikarinen L, Nieminen MS, Toivonen L, et al. Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention For Endpoint Reduction (LIFE) study. *Am Heart J* 2003;145:919-25.
40. Gonzalez-Juanatey JR, Garcia-Acuna JM, Pose A, et al. Reduction of QT and QTc dispersion during long-term treatment of systemic hypertension with enalapril. *Am J Cardiol* 1998;81:170-4.
41. Langenickel TH, Jordaan P, Petruck J, et al. Single therapeutic and suprathreshold doses of sacubitril/valsartan (LCZ696) do not affect cardiac repolarization. *Er J Clin Pharmacol* 2016;72:917-24.
42. Burch GE. Development in clinical electrocardiography since Einthoven. *Am Heart J* 1961;61:324-46.
43. Carter EP, Andrus EC. Q-T interval in human electrocardiogram in absence of cardiac disease. *JAMA* 1922;78:1922.
44. Currens JH, Crawford JD. The electrocardiogram and disturbance of potassium metabolism. *N Engl J Med* 1950;243:843-50.
45. Reynolds TB, Martin HE, Homann RE. Serum electrolytes and the electrocardiogram. *Am Heart J* 1951;4:671-81.
46. Merrill AJ. The significance of the electrocardiogram in electrolyte disturbances. *Am Heart J* 1952;43:634-9.
47. Burch GE. The electrocardiogram and disturbances in electrolyte balance. *Arch Intern Med* 1954;94:509-12.
48. Bellet S. The electrocardiogram in electrolyte imbalance. *Arch Intern Med* 1955;96:618-38.
49. Goodwin JF. The cardiographic assessment of electrolyte imbalance. *Proc R Soc Med* 1958;51: 801-6.
50. Ramirez AH, Schildcrout JS, Blakemore DL, et al. Modulators of normal electrocardiographic intervals identified in a large electronic medical record. *Heart Rhythm* 2011;8:271-7.

KEY WORDS cohort studies, electrocardiographic intervals, electrolytes, epidemiology, meta-analysis